Compass Pathways Launches Change the Tune in TRD
LONDON and NEW YORK — September 15, 2026 Compass Pathways plc announced the launch of Change the Tune in...
Most Recent
Advertisement
Nanobiotix Advances JNJ-1900 in Recurrent NSCLC
PARIS, France and CAMBRIDGE, Mass. — September 14, 2026 Nanobiotix announced complete Phase 1 safety and efficacy findings for...
Pulse Biosciences Completes PRECISE-BTN Enrollment
HAYWARD, Calif. — September 15, 2026 Pulse Biosciences, Inc. announced completion of enrollment in the PRECISE-BTN clinical study evaluating...
Syntis Bio Advances Oral SYNT-101 Toward Phase 2
BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...
Rocket Pharmaceuticals Advances RP-A501 Toward Danon Disease Approval
CRANBURY, N.J. — September 15, 2026 Rocket Pharmaceuticals, Inc. announced alignment with the U.S. Food and Drug Administration (FDA)...
One04 Therapeutics Launches With CPV-104 Clinical Expansion
FREIBURG, Germany — September 15, 2026 One04 Therapeutics GmbH & Co. KG announced its launch as a clinical-stage biopharmaceutical...
ENA Respiratory Advances INNA-051 Into Part B Phase IIa
MELBOURNE, Australia — September 15, 2026 ENA Respiratory announced that the first participants have been dosed in Part B...
Acurx Pharmaceuticals Presents Ibezapolstat C. difficile Data
New York, New York, September 15, 2026 Acurx Pharmaceuticals has announced the presentation of new preclinical microbiology data for...
QurCan Therapeutics and Lilly Advance Nucleic Acid Therapies
Cambridge, Massachusetts, September 15, 2026 QurCan Therapeutics has entered into a strategic research and collaboration agreement with Eli Lilly...
Ocular Therapeutix Advances AXPAXLI Toward Wet AMD NDA
BEDFORD, Mass. — September 15, 2026 Ocular Therapeutix, Inc. announced the successful completion of its Pre-New Drug Application (Pre-NDA)...
Advertisement
